Sandeep Chidambar Kulkarni insider trades: Tourmaline Bio (TRML) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Sandeep reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 21, 2024 | TRML | ↑ Buy | 1,779 | $14.85 | $26K | By Gilead Capital, LP | Aug 22, 2024 (1d) |
| Aug 16, 2024 | TRML | ↑ Buy | 5,221 | $13.79 | $72K | By Gilead Capital, LP | Aug 20, 2024 (4d) |
| Nov 17, 2023 | TRML | ↑ Buy | 4,000 | $16.99 | $68K | Direct | Nov 20, 2023 (3d) |
| Oct 26, 2023 | TRML | ↑ Buy | 9,650 | $11.49 | $111K | Direct | Oct 26, 2023 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Sandeep Chidambar Kulkarni's insider trades
Sandeep Chidambar Kulkarni is CEO at Tourmaline Bio (TRML). Since Oct 26, 2023, Sandeep has reported 4 open-market purchases worth $277K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (7 filings), other transactions (2 filings), shares returned to the company (1 filing), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TRML insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.